Goldman Sachs Lifts Estimates and Price Target On Allergan (AGN) After Botox for Migraines

October 18, 2010 7:19 AM EDT
Get Alerts AGN Hot Sheet
Price: $193.02 --0%

Rating Summary:
    10 Buy, 21 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 5 | New: 58
Trade Now! 
Join SI Premium – FREE
Goldman Sachs raised estimates and their price target on Allergan, Inc. (NYSE: AGN) following early approval of Botox for use in migraines.

2011-2013 EPS rise by 2-5% to $3.77, $4.44 and $5.28.

The firm's price target raises from $81 to $84.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments